strong solid guid eclips
concern migrat reiter op
fundament impress drive better-than-expect organ
growth vs cs ep beat sale bil
mil estim driven upsid nutrit mil
devic mil partial off-set diagnost mil despit
strong result concern potenti impact medicar put
pressur healthcar
even though view probabl becom law quit
low probabl also earli tell whether today overhang
temporari last said remain bullish abt
fundament reiter outperform rate rais target slightli
libr mitraclip hf lead devic growth diabet sale
led freestyl libr libr current fda
review icgm approv alarm data commun everi
second management pursu coverag new fmr indic
mitraclip took month dmr could arguabl move faster
given collabor track record structur heart
management focus execut growth opportun pipelin debt
repay remain focus key growth opportun howev
reduc leverag make strateg invest option said
manag view current market target-rich environ
valuat target price previous base ebitda
multipl unch estim ntm ebitda month forward bil
bil risk sustainability/vis epd em fx exposur
potenti delays/failur new product approv
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global manufactur provid
diversifi healthcar product medic devic equip
area nutrit diagnost vascular intervent
diabet coronari endovascular structur heart
price apr rate outperform target price analyst matt miksic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base emerg segment deliv
growth high-growth segment grow growth
grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base emerg segment deliv
growth high-growth segment grow growth
grow
 close
addit detail takeaway
nutrit bil mil y/i cc organ
ww pediatr nutrit sale bil mil increas organ
reflect unfavor fx vs perform led strong
growth asia latin america well broad-bas growth across infant toddler
brand ww adult nutrit sale mil mil increas organ
perform quarter driven strong growth ensur glucerna diabet
specif nutrit brand manag expect nutrit grow low mid-singl digit
diagnost bil mil y/i cc organ
laboratori diagnost sale bil mil increas
organ reflect above-market growth ou led strong adopt
alin molecular diagnost sale mil mil decreas
organ basi reflect unfavor fx point diagnost sale
mil mil decreas organ rapid diagnost sale mil
mil decreas decreas organ strong growth cardio-
metabol test infecti diseas test off-set difficult comp last year due
strong flu season manag expect diagnost grow mid high singl digit
legaci diagnost busi full year rapid diagnost expect
grow low mid singl digit
establish pharma mil mil y/i cc
sale key emerg market india brazil russia china decreas
organ basi reflect unfavor fx em sale decreas
organ sale neg impact quarter recent discontinu
suppli agreement context agreement manufactur third parti
end earlier expect result mil hit quarter manag
expect establish pharma grow mid-singl digit reflect mid high
singl digit em off-set modest declin epd sale
devic bil mil y/i cc organ
electrophysiolog mil sale market compani
get readi launch new tacticath contact forc ablat cathet receiv
fda approv januari growth structur heart mil broad base
quarter compani receiv fda approv expand indic
mitraclip treat clinic signific secondari mr result underli heart failur
compani await reimburs approv expect take
month current implant center expect number
rise time diabet mil sale increas
organ led rapid market uptak freestyl libr report sale mil
organ approxim libr sale reimburs intern
countri half live cover commerci libr current
fda review type diabet make compani user base mil
libr user mil libr user ww mil last quarter heart
failur mil growth driven uptak heartmat lvad manag
expect medic devic grow high singl digit
 oper margin bp estim
bottom line sale net cog higher non-op incom
partial off-set higher sg deliv upsid ep deliv ep
estim consensu gross margin bp
estim bp last year
compani maintain ep guidanc full-year organ
growth fx expect neg impact full year
report sale vs guidanc expect gross margin somewhat
 sg around compani guid organ sale
growth around ep fx expect neg impact
sale
sale
sale
estimate
ep
sale
sale
point care
estimate
charl martineau pm univers toronto chang model
beyond make modest adjust top-lin estim
bottom-lin increas year estim
figur chang model
target price previous base unchang ntm ebitda
charl martineau pm univers toronto compani mention price
